11 C]Preladenant was developed as a novel adenosine A 2A receptor positron emission tomography radioligand. The present study aims to evaluate the suitability of [ 11 C]preladenant positron emission tomography for the quantification of striatal A 2A receptor density and the assessment of striatal A 2A receptor occupancy by KW-6002. Sixty-or ninety-minute dynamic positron emission tomography imaging was performed on rats. Tracer kinetics was quantified by the two-tissue compartment model, Logan graphical analysis and several reference tissue-based models. Test-retest reproducibility was assessed by repeated imaging on two consecutive days. Two-tissue compartment model and Logan plot estimated comparable distribution volume (V T ) values of $10 in the A 2A receptor-rich striatum and substantially lower values in all extra-striatal regions ($1.5-2.5). The simplified reference tissue model with midbrain or occipital cortex as the reference region proved to be the best non-invasive model for quantification of A 2A receptor, showing a striatal binding potential (BP ND ) value of $5.5, and a test-retest variability of $5.5%. The brain metabolite analysis showed that at 60-min post injection, 17% of the radioactivity in the brain was due to radioactive metabolites. The ED 50 of KW-6002 in rat striatum for i.p. injection was 0.044-0.062 mg/kg. The study demonstrates that [ 11 C]preladenant is a suitable tracer to quantify striatal A 2A receptor density and assess A 2A receptor occupancy by A 2A receptor-targeting molecules.
Introduction
Adenosine is a signaling molecule that functions via activation of four subtypes of adenosine receptors, referred to as A 1 , A 2A , A 2B , and A 3 . The adenosine A 2A receptor (A 2A R) subtype is expressed predominantly in the basal ganglia of the central nervous system (CNS). 1 The A 2A R plays an important role in modulating dopamine and glutamate neurotransmission, and regulating neuroinflammation. [2] [3] [4] [5] [6] Therefore, A 2A R is generally associated with neurological and psychiatric disorders related to neuroinflammation and/or disturbed dopamine/ glutamate signaling pathways, such as Huntington's disease (HD), Alzheimer's disease (AD), depression, schizophrenia, and Parkinson's disease (PD). 7, 8 A 2A R may act as a diagnostic biomarker in, for instance, HD and PD, [14] [15] [16] [17] which could allow monitoring of disease progression.
Positron emission tomography (PET) with a suitable A 2A R radioligand can be used to exploit the potential of A 2A R as a biomarker by measuring its distribution and density. Furthermore, PET may also be a suitable technique to monitor changes in A 2A R expression in the brain during the course of the disease, or to assess A 2A R occupancy after administration of an (investigational) drug. The latter could be important for drug development, e.g. for establishing the optimal dosing regimen. [ 18 F]MNI-444, [ 11 C]TMSX, [ 11 C]KW-6002, and [ 11 C]SCH442416 are A 2A R PET ligands that have been studied in human subjects. [16] [17] [18] [19] [20] [21] [22] [ 18 F]MNI-444 displayed best properties among these tracers, with binding potential (BP ND ) values ranging from 2.6 to 4.9 in A 2A R-rich regions, and an average test-retest variability (TRV) of less than 10%. 18 Other tracers are hardly useful for A 2A R quantification, because of the disadvantages such as low BP ND in striatum, high extra-striatal binding and low target-to-non-target ratios. 16, 17, [19] [20] [21] [22] We have recently developed [ 11 C]preladenant, the C-11 labeled analog of the drug preladenant. The in vivo assessment of this tracer in rats showed a better contrast in the PET images (i.e. larger striatum-tocerebellum ratio) than published for other A 2A R radioligands in rat studies. [23] [24] [25] [26] [27] The results suggest a great potential of [ 11 C]preladenant to image A 2A R in the brain. Another advantage of [ 11 C]preladenant is that the toxicological profile of preladenant in humans is already known from clinical phase I/II/III studies, in which preladenant was investigated as a drug. 28 Therefore, expensive toxicity studies are not required anymore and the costs and timeline of tracer development can be reduced.
To determine the suitability of [ 11 C]preladenant PET for A 2A R quantification, we further evaluated the tracer by assessing pharmacokinetic modeling, testretest reproducibility, and the feasibility of measuring A 2A R occupancy in the rat brain.
Materials and methods
(E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7dhydro-1H-purine-2,6-dione (KW-6002) was purchased from Axon Medchem BV (Groningen, The Netherlands).
Radiosynthesis [ 11 C] Preladenant was prepared according to the method described by Zhou et al. 27 The specific activity of [ 11 C]preladenant was 81 AE 33 GBq/mmol (n ¼ 26), and the radiochemical purity was always greater than 98%.
The tracer was formulated in $15% ethanol in phosphate buffered saline as final product.
Animals
Adult male Wistar rats (n ¼ 37, Hsd/Cpb:WU, 9-11 weeks age, 300-400 g, Harlan, The Netherlands) were housed in groups at a 12 h light/12 h dark circle and were fed with standard laboratory chow (RMH-B, The Netherlands) and water ad libitum. After arrival from the supplier, rats were acclimatized for at least 7 days. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Groningen (DEC 6689B and DEC 6689G) and conducted in accordance with the Law on Animal Experiments of The Netherlands. All the animal study data were reported according to ARRIVE guidelines (Animal Research: Reporting In Vivo Experiment).
Brain metabolite analysis
The animals were sacrificed by extirpation of the heart at 60-min post injection. The brain was extracted and half of the brain (sagittal section) was homogenized with 1 mL of acetonitrile and then centrifuged at 3000 g for 3 min. The supernatant was filtered through a 0.45 mm Durapore (PVDF) filter (Millipore, Billerica, MA, USA). Samples (100 mL) were subsequently injected to a ultra-high performance liquid chromatography (UPLC) using an Acquity UPLC HSS T3 UHPLC column (1.8 mm, 3.0 Â 50 mm 2 ) at a column temperature of 40 C and a gradient containing water (pH ¼ 2 with HClO 4 ) and acetonitrile as mobile phase with flow rate of 1.1 mL/ min. The eluted fractions were collected every 30 s and measured with an automated well-counter (Compugamma 1282 CS, LKB-Wallac, Turku, Finland). The percentage of radioactive metabolites in the brain tissue was calculated as 100% À (total activity of intact tracer À activity of intact tracer in blood at 60-min post injection Â 5%)/(total activity À total activity in blood at 60-min post injection Â 5%) Â 100%.
PET imaging
Prior to PET imaging, animals were anesthetized with isoflurane in medical air (5% isoflurane for induction, 1.0-2.5% isoflurane for maintenance) and kept on electronic heating pads during the study to avoid hypothermia. Cannulas were placed in a femoral vein for tracer injection and in a femoral artery for blood sampling. Six rats were i.p. injected with vehicle (50% dimethylacetamide (DMA) in saline) and six rats were i.p. injected with KW-6002 (1 mg/kg) in a 1 mg/mL solution of 50% DMA in saline 7-10 min prior to tracer injection. PET images were acquired using a Focus220
MicroPET scanner (Preclinical solutions, Siemens Healthcare Molecular Imaging, USA Inc.). Two rats were scanned simultaneously. The brains of both rats were positioned close to the center of the field of view. A transmission scan with a 57 Co point source was made for attenuation correction. Rats were i.v. injected with 66 AE 23 MBq (2.1 AE 1.7 nmol) [ 11 C]preladenant at a speed of 1 mL/min with an infusion pump for 1 min, and a 60-min dynamic PET scan was started. The injected mass was estimated to occupy 1.6 AE 1.2% A 2A Rs in rat striatum at the maximum uptake, being a standardized uptake value (SUV) of 2.2, and an A 2A R density of 953 fmol/mg protein. 29 Blood samples (each sample of 0.10-0.13 mL, 1.5-1.8 mL in total) were drawn from the femoral artery at 10, 20, 30, 40, 50, 60, 90 s and 2, 3, 5, 7.5, 10, 15, 30, 60 min after tracer administration. In all, 0.10-0.13 mL saline with 1% heparin was infused into the artery after each sampling to compensate for the blood loss. Radioactivity in 25 mL whole blood and 25 mL plasma (acquired by centrifugation of blood samples for 5 min at 1000 g) were measured with an automated well-counter and used as an arterial input function (with metabolite correction). List mode acquisition data was divided in 21 frames (6 Â 10, 4 Â 30, 2 Â 60, 1 Â 120, 1 Â 180, 4 Â 300, and 3 Â 600 s). The data were reconstructed per time frame using an attenuation-weighted 2-dimensional ordered-subset expectation maximization algorithm (AW-OSEM2D). The 95 sagittal slices with a slice thickness of 0.8 mm were separated into one image for both rats with a 128 Â 128 matrix and a pixel size of 0.47 Â 0.47 mm 2 . Datasets were fully corrected for random coincidences, decay, scatter, and attenuation.
PET data analysis
Summed PET images were manually aligned to a T2 magnetic resonance imaging (MRI) template of a rat brain with predefined volumes of interest (VOIs) for whole brain, total cortex, frontal cortex, occipital cortex, parietal cortex, striatum, midbrain, thalamus, hippocampus, and cerebellum. Time-activity curves (TACs, expressed as Bq/cc) for different VOIs were generated using Inveon Research Workplace software (Siemens Medical Solutions, Knoxville, TN), and were normalized to body weight (g) and injected dose (Bq) to obtain dynamic SUVs.
Tracer kinetic modeling
TAC data were analyzed using PMOD software (version 3.5, PMOD Technologies, Zu¨rich, Switzerland). A mono-exponential function was fitted to a populationbased intact tracer fraction obtained from our previous study. 27 The blood volume in the brain was fixed to 5%, as the volume did not significantly affect distribution volume (V T ) estimation, being $1% difference between 5% (ref. 30, 31) and 3.6% (ref. 32 ) fits, and $4% difference between 5% and 0% fits, whereas 5% blood volume fit gave smaller Akaike Information Criterion (AIC) values compared with 3.6% or 0% blood volume fits. A standard two-parameter (K 1 , k 2 ) onetissue compartment model (1TCM) and a four-parameter (K 1 , K 1 /k 2 , k 3 , k 4 ) two-tissue compartment model (2TCM), both with a metabolite corrected plasma input function, were used to fit the TACs. The best fitting model was selected based on AIC values. The V T was obtained by modeling with the 2TCM and the Logan graphic analysis with t* set to 10 min. Several reference tissue-based models, including simplified reference tissue model (SRTM), Ichise's multilinear reference tissue model (MRTM) with t* set to 1 min, Ichise's multilinear reference tissue model 2 (MRTM2) with t* set to 1 min, and the reference tissue Logan plot (RLogan) with t* set to 5 min were used to estimate the BP ND in striatum. The t* was selected based on the goodness of fit, resulting V T or BP ND value (larger is better), and coefficient of variation (COV) of V T or BP ND (smaller is better). Cerebellum, midbrain, hippocampus, and occipital cortex were tested as reference regions. BP ND obtained from the reference tissuebased models were compared with BP ND obtained from k 3 /k 4 (direct method) and calculated from the V T determined with the 2TCM and the Logan plot using the formula BP ND ¼ ðV T À V ND Þ=V ND (ref. 33 ). The best reference regions were selected based upon the testretest reliability, the BP ND value in striatum, and between-subject variability of BP ND .
Test-retest
To estimate test-retest reliability, five rats underwent two PET scans on consecutive days. The PET scans were performed as described above but without cannulation, blood sampling and KW-6002 or vehicle pretreatment. BP ND in striatum was determined using SRTM, RLogan, MRTM, MRTM2, and SUV ratio (SUV r ) -1, using different reference regions. The SUV was the average SUV value from 25 till 60-min post injection. TRV was defined as
The test-retest reliability was quantified using intraclass correlation coefficient (ICC) with a one-way random effects model ICC (1, 1) (ref. 34):
where BMS is the mean sum of squares between subjects, WMS is the mean sum of squares within subjects, and k is the number of measurements, being 2 for testretest. ICC was measured on a scale ranging from À1 to 1. One represents perfect reliability, whereas À1 indicates no reliability. An ICC ! 0.75 is considered as a good reliability. 35 The ICC was computed using R (http://www.r-project.org/).
A 2A R occupancy
Eight baseline PET scans and 12 scans after administration of the selective A 2A R antagonist KW-6002 were performed as described above but now without cannulation and blood sampling. The emission scan was extended to 90 min. 
where BP ND was derived from SRTM, RLogan, SUV r -1, and modified SUV ratio (mSUV r ) -1, using midbrain, cerebellum, or occipital cortex as the reference region. The modification factors for mSUV r -1 were determined by Deming linear regression between SUV r -1 and SRTM or RLogan derived BP ND . The occupancy (%) was plotted against the drug dose and the dose-occupancy curve was fitted in GraphPad Prism (version 5.01, GraphPad Software, Inc.) with a one site-specific binding model using the following formula:
where Occ max is the maximum occupancy, ED 50 is the drug dose which corresponds to 50% occupancy, and D is the drug dose. The striatal BP ND and ED 50 were estimated from the 90-min acquisition as well as from the first 60 min of this acquisition. The values from both estimates were compared.
Statistics
All results are expressed as mean AE standard deviation (SD). Unpaired two-tailed t-test with Bonferroni correction for multiple comparisons was used to assess the difference in plasma activity between vehicle and KW-6002 pretreatment groups. Paired two-tailed ttest with Bonferroni correction for multiple comparisons was used to assess the difference between BP ND and (m)SUV r -1, the difference in BP ND between direct method and indirect methods, and the difference in COV between 60-and 90-min acquisitions. Two-way ANOVA with Bonferroni post-tests was used to evaluate the effects of KW-6002 pretreatment and VOIs on V T and BP ND . Repeated measures two-way ANOVA with Bonferroni post-tests was used to assess the difference in AIC, V T , and BP ND between models and VOIs, the difference in BP ND between test-retest and VOIs/ models, and the difference in BP ND between acquisition times and VOIs. Bland-Altman plot (difference (Á) vs. mean) and one sample t-test were used to judge the bias (Á) in BP ND obtained from Logan plot and reference tissue-based modeling methods as compared with BP ND calculated from 2TCM. Á (%) was computed as
where BP ND,1 was derived from 2TCM, Logan plot, SRTM, MRTM, and RLogan, and BP ND,2 was always calculated from 2TCM. Deming linear regression was used to compare acquisition durations, and SUV r -1 and BP ND . A probability value (p) < 0.05 was considered statistically significant.
Results
Plasma clearance and brain metabolism of The plasma curves were corrected with a mono-exponential fitted population-based intact-tracer function. The metabolite corrected plasma curve at baseline was well described with a two-phase exponential function, with a t 1/2 a of 0.59 AE 0.37 min, and t 1/2 b of 22.24 AE 4.68 min (n ¼ 6). At 60-min post tracer injection, 17 AE 5% (n ¼ 3) of the total activity in the brain tissue was due to the radioactive metabolites.
Tracer kinetic modeling
The tracer kinetics in rat brain is better described with a 2TCM with a fixed blood volume of 5% than a 1TCM with a fixed blood volume of 5% (Figure 1(b) and (c)). The 2TCM fits showed significantly (p < 0.001) lower AIC values compared with 1TCM fits (Bonferroni posttests), whereas no difference in average AIC values was observed between brain regions, and there was no interaction between model and VOI (repeated measures two-way ANOVA). For the striatal TAC (Figure 1(b) ), the 2TCM fitted the data much better than the 1TCM, particularly for the first 10 min. In the extra-striatal regions, 1TCM failed to describe the later time points of TACs (Figure 1(c) ). V T was estimated by 2TCM and Logan graphic analysis ( Table 1) . The effects of model and brain region on V T at baseline were analyzed. There was a strong interaction between model and brain region (p < 0.001), and both model and VOI significantly (p < 0.001) affected average V T (repeated measures two-way ANOVA). Striatal V T determined by the 2TCM was 10.5 AE 1.9, which was slightly (5.8%) but significantly (p < 0.001) higher compared with V T estimation by Logan plot (9.9 AE 1.7). Both models provided comparable V T values of $1.5 in extra-striatal regions (Bonferroni post-tests). KW-6002 pretreatment significantly (p < 0.001) reduced the V T in striatum to $2.0, whereas no significant difference was found between vehicle and KW-6002 pretreatment in other brain regions (two-way ANOVA with Bonferroni post-tests). The V T data of parietal cortex, frontal cortex, thalamus, cortex total, and whole brain are listed in Supplementary Table 1 and are not discussed here, because these brain regions are affected by spillover from striatum and harderian glands with high tracer uptake. Several reference regions, including midbrain, hippocampus, cerebellum, and occipital cortex were selected and tested in reference region models to predict BP ND . These selected regions are relatively large brain structures lacking A 2A R specific binding sites. 36 Furthermore, they are away from striatum and harderian glands, so that the spill-over effect is avoided. Therefore, the V T values obtained from these regions were smaller and more stable than the values of other extra-striatal regions
) and were not affected by the KW-6002 pretreatment ( Table 1 and Supplementary Table 1 ). Such properties make them the suitable candidates as reference regions to calculate striatal BP ND . BP ND values estimated by k 3 /k 4 (direct method) are shown in Supplementary Table 2 . The BP ND values were significantly (p < 0.001) different among brain regions for vehicle/KW-6002 treatment. Both treatment and VOI strongly (p < 0.001) affected average BP ND (two-way ANOVA). Striatal BP ND in vehicle treated animals was 9.17 AE 1.90, the value was significantly (p < 0.001) reduced to $1.38 AE 0.63 with KW-6002 pretreatment, whereas the pretreatment did not alter the BP ND in reference regions (Bonferroni post-tests). Striatal BP ND at baseline was also obtained by indirect methods using a reference region ( Supplementary Table  3 ). Indirect methods estimated similar BP ND values of 5.0-6.1, which were $40% smaller than BP ND calculate from the direct method. However, the between-subject variability with indirect methods (8-19% COV) was smaller than the variability of the direct method (20% COV). Indirect methods with midbrain or hippocampus as the reference tissue seemed to produce less variable results ($10% COV), compared with other reference regions ($17% COV) ( Supplementary Table  3 and Figure 2 ). Midbrain as the reference region estimated significantly (p < 0.05) higher BP ND values in striatum, regardless of the model used (repeated measures two-way ANOVA with Bonferroni post-tests). We compared various reference regions for the striatal BP ND values at baseline obtained from Logan plot and reference tissue-based modeling methods with the BP ND calculated from 2TCM as the gold standard. Relative to the 2TCM, a significantly (p < 0.05) negative bias (Á) (up to 13.2%) was found with Logan plot and reference tissue-based methods for all reference regions in most cases (one-sample t-test) (Figure 2 and Supplementary Table 4 ). Such bias was also demonstrated by the linear regression of the striatal BP ND values obtained from SRTM and RLogan against BP ND values calculated from 2TCM, showing slopes of 0.91 for RLogan and 0.87 for SRTM when the midbrain was used as the reference region ( Supplementary Figure 1) . SRTM and MRTM estimated comparable k 2 ' values (Supplementary Table 5 ). The variability was slightly smaller with SRTM than MRTM. Therefore, k 2 ' values determined by SRTM (0.39 AE 0.06 À 0.45 AE 0.02 min À1 ) were used in RLogan and MRTM2.
Test-retest
Test and retest BP ND values for SRTM, RLogan, and SUV r -1 are presented in Table 2 . TRV and ICC for all methods are listed in Supplementary Table 6 . The average retest BP ND values were significantly (p < 0.01) smaller than the test results, and such difference was comparable between VOIs or models, whereas differences in VOI or model did not significantly affect average BP ND (repeated measures two-way ANOVA), nor the test and retest BP ND values (Bonferroni post-tests). The average TRV was less than 10%, which was similar across VOIs and models. The ICC values were fairly homogenous for all VOIs and models, ranging from 0.83 to 0.94, except for models with hippocampus as the reference region, showing an ICC of 0.38-0.43. Because of lacking of test-retest reliability, hippocampus was no longer assessed in the occupancy study. Occipital cortex displayed the lowest within-subject variability (TRV ¼ 4.6-6.4%) and highest test-retest reliability (ICC ¼ 0.91-0.94) compared with other reference regions. Since MRTM and MRTM2 did not show better results compared with SRTM and RLogan in terms of resulting BP ND value and the inter-/intra-subject variability of BP ND , these bi-linear regression methods were not assessed in the occupancy study.
A 2A R occupancy
Pretreatment of KW-6002 at 15-25 min before administration of [ 11 C]preladenant decreased the tracer uptake in striatum in a dose-dependent manner (Figure 3 ). BP ND in striatum was determined by SRTM, RLogan, and (m)SUV r À 1 with a static scan duration of 35 min, starting at 25-min post injection, using midbrain, cerebellum, or occipital cortex as the reference region. The correlation between striatal BP ND obtained from 90-min acquisition and from 60-min acquisition was studied using Deming linear regression. The BP ND values at 60 min were plotted against BP ND values at 90 min (Figure 4(a) and (b) ). Both SRTM and RLogan showed a strong correlation between acquisition times, with slopes close to 1 (1.00-1.03) and a very small y-intercept of around 0.06. In comparison with the 60-min acquisition, the 90-min acquisition estimated marginally smaller (1.8-3.6%) BP ND Figure 2 . Bland-Altman plot for midbrain (a), hippocampus (b), cerebellum (c), and occipital cortex (d) with different modeling methods to obtain striatal BP ND . Avg BP ND ¼ ðBP ND,1 þ BP ND,2 Þ=2, Á ¼ 2 Â 100 Â ðBP ND,1 À BP ND,2 Þ=ðBP ND,1 þ BP ND,2 Þ, where BP ND,1 was derived from 2TCM (black square), Logan plot (black cross), SRTM (red triangle), MRTM (green circle), and RLogan (blue diamond), and BP ND,2 was always calculated from 2TCM. Each point represents the data of an individual animal (n ¼ 6). BP ND obtained from 2TCM and Logan plot was calculated from the V T using the formula BP ND ¼ ðV T À V ND Þ=V ND . 2TCM: two-tissue compartment model; SRTM: simplified reference tissue model; MRTM: multilinear reference tissue model; RLogan: reference tissue Logan plot. values at baseline. Deming linear regression was also used to assess the correlation between SUV r -1 and BP ND derived from pharmacokinetic modeling for 60min acquisition (Figure 4(c) and (d) ). A high agreement was found between these methods, indicating that SUV r -1 is also a robust parameter to predict BP ND . The striatal BP ND can be calculated from SUV r -1 corrected by the following equation:
where the y-intercept and slope were obtained from Deming linear regression (Figure 4(c) and (d) ).
To estimate the ED 50 of KW-6002, the doseoccupancy curve was fitted with the equation:
The hillslope was calculated to be approximately 1, indicating the binding pattern of monomer one-site binding. Then the hillslope value was fixed to 1 for all calculations. Occ max (maximum occupancy) was estimated to be $87-103% with a standard error of $4-6%, and a 95% confidence interval of 73-123% for the tested reference regions and models. A 2A R occupancy as well as ED 50 estimates were similar between models and scan durations with the same reference regions (<10% difference between models and <5% difference between acquisition times) ( Figure 5 ). However, larger differences in ED 50 estimation were observed between reference regions: KW-6002 ED 50 estimates for i.p. injection were 0.056 AE 0.003, 0.062 AE 0.002, and 0.044 AE 0.002 mg/kg for midbrain, cerebellum, and occipital cortex as the reference region, respectively.
Discussion
This study demonstrates that [ 11 C]preladenant is a suitable PET tracer for the quantification of available A 2A R binding sites in the rat brain. The tracer displayed high uptake in striatum and low and homogenous uptake in all extra-striatal regions. The regional distribution of [ 11 C]preladenant is in agreement with the known A 2A R expression in the rat brain, 36 as the receptors are predominantly expressed in striatum only. An A 2A R subtype selective antagonist, KW-6002 (K i value: 37) ) significantly reduced the tracer uptake in striatum by 80%. However, the V T in striatum was till 40% higher than the values in the reference brain regions ( is a good tool to aid the development of A 2A R drugs if confirmed in humans. Several plasma input-dependent (2TCM and Logan plot) and reference tissue-based (SRTM, MRTM, MRTM2, and RLogan) modeling methods as well as (m)SUV r -1 were applied to calculate V T and/or BP ND . Regarding the BP ND estimation, four reference regions have been tested with indirect models. There are two purposes to test different reference regions: (a) to find proper reference regions with negligible receptor expression, which are able to estimate target BP ND with high value, low standard error, and a high testretest reproducibility; and (b) to have suitable alternative reference regions. Because A 2A Rs are also expressed in glial cells that are involved in regulating neuroinflammation, A 2A R tracers could also be used to study A 2A R changes in animal models with neuroinflammation, for example, the herpes simplex virus infected rat model. In this case, midbrain and cerebellum are not proper reference regions anymore, because these regions are affected by the virus and associated with an increased level of A 2A R. Then, we may choose a less infected region (occipital cortex) as the reference region instead.
V T and BP ND predictions with all models and reference regions were in agreement with each other, except for the striatal BP ND estimation with the direct method, which was about 60% larger than the BP ND estimated by indirect methods. Indirect methods might have underestimated BP ND because of (a) the presence of radioactive metabolites in the brain, which contributed $17% of the total activity in the brain at 60-min post injection. The brain metabolites reduced the target-tobackground ratio, leading to an underestimation in BP ND when the indirect methods were applied. When the V T values were corrected by subtracting the V T contribution by 17% radioactive metabolites, the BP ND calculated from BP ND ¼ ðV T À V ND Þ=V ND became $8.9, which was comparable with k 3 /k 4 of 9.2. Also because of the radioactive metabolites in the brain, when the 2TCM was used to fit tracer TACs, a specific distribution volume of 0.6-1.1 was found in reference regions which was not affected by KW-6002 blockade. The presence of radioactive metabolites could also explain the difference between the direct method and indirect methods derived BP ND in striatum with KW-6002 pretreatment ( Supplementary Tables 2  and 3 ). The brain metabolite could theoretically be a problem with this tracer. However, it didn't show much effect on the BP ND stability, as only $3% difference was observed in BP ND between 90-min and 60-min acquisition data; (b) noise-induced negative bias with graphical analysis. 38 For Ichise's multilinear regression, it was shown that a 5% average noise in the TAC can result in a 75% underestimation of BP ND at a true BP ND of 3 (ref. 39) . Such underestimation is more pronounced at high noise level and high actual V T and BP ND ; (c) Violations of assumptions with SRTM fit. 40 For example, the tracer kinetics could be fitted well with the 2TCM, but not with the 1TCM. Such violation resulted in an underestimation of BP ND . On the other hand, the BP ND calculated from the direct method might be biased due to the polar radioactive metabolites penetrating the blood-brain-barrier. Reference tissue-based BP ND values displayed much lower variability ($10% COV) compared with the variability of k 3 /k 4 and V T ($18-20% COV) in striatum. This is a well-known aspect of reference tissue models and is related to the number of fit parameters. V T seems to be more variable than BP ND , probably due to the variability in the plasma sample measurements. Therefore, we consider that BP ND predicted from indirect methods is more robust than k 3 /k 4 and V T .
In addition, we compared the striatal BP ND values predicted from different reference tissue models, using 2TCM as the gold standard. BP ND estimated from reference tissue-based models correlated well (R 2 > 0.99) with 2TCM estimation (Supplementary Figure 1) . However, a small (up to 13.2%) negative bias (Supplementary Table 4 ) was observed with reference tissue-based methods. Here, we consider that the accuracy in BP ND prediction is less important than other properties like the robustness of model-parameter values and the model complexity. Therefore, BP ND derived from reference tissue-based modeling methods was used to study the test-retest reproducibility of [ 11 C]preladenant PET and to characterize A 2A R occupancy.
The test-retest experiment showed that the striatal BP ND values for the retest were slightly lower (<10%) with $10% larger between-subject variability compared with test values. The receptor occupancy by the PET tracer during the test scan was estimated to be $2-7%, provided an A 2A R density of 300-953 fmol/mg protein in striatum. 1, 29, 41 We assume that the occupancy decreased at least 60% after 24 h (ref. 42), then $1-3% of the receptors were occupied by the cold tracer. However, this number cannot completely explain the underestimation of 4-9% with retest. Therefore, we consider that other factors such as anesthesia during the test scan may lead to the underestimation of BP ND with retest.
In addition, we compared BP ND and ED 50 values obtained from the 90-min acquisition with the values obtained from the 60-min acquisition in the occupancy study. The BP ND as well as ED 50 predictions were very similar between models and acquisition times (Figures 4  and 5 ). The slightly (<3%) higher BP ND values at baseline obtained from the 60-min acquisition could be explained by the slow accumulation of radioactive metabolites in the brain, leading to a reduced BP ND value for 90-min acquisition. Furthermore, 60-min acquisition showed improved precision in BP ND prediction, with significantly (p < 0.05) lower COV compared with COV of 90-min acquisition. Therefore, 60-min acquisition provides better estimation of BP ND in rat brain, compared with 90-min acquisition.
The kinetic modeling and test-retest experiments showed that all reference tissue-based models, including SRTM, MRTM, MRTM2, and RLogan with different reference brain regions, including midbrain, cerebellum, and occipital cortex provided comparable results, with a high BP ND value in striatum with small betweensubject variability and high test-retest reliability. However, in comparison with midbrain and occipital cortex, cerebellum seems to be less favorable, with a slightly higher between-subject and TRV than the other two reference regions.
In the A 2A R occupancy study, $30% difference was found in ED 50 prediction between modeling methods using occipital cortex as the reference region and models using midbrain or cerebellum as the reference region. It is difficult to determine which value is more reliable and which reference region is better than the rest in the A 2A R occupancy study, since the 95% confidence interval for ED 50 is quite wide for all methods, being around 0.02-0.09 mg/kg ( Figure 5 ). Taking into account factors like the need of blood sampling, complexity of the model, intra-and inter-individual variability, and the value of BP ND in striatum, we consider that SRTM with midbrain or occipital cortex as the reference tissue to be the preferable model for striatal A 2A R quantification, as SRTM is simpler than RLogan and MRTM2, which require a priori k 2 ' estimation, and SRTM is slightly more robust than MRTM ( Supplementary Table 6 ).
An interesting finding in this study is the suitability of SUV r to predict striatal BP ND , in terms of comparable COV and test-retest reliability between SUV r -1 and BP ND ( Table 2 and Supplementary Table 6 ), a strong correlation between the two parameters (Figure 4(c) and (d) ), and the feasibility of (m)SUV r -1 to study A 2A R occupancy ( Figure 5(c) and (f) ). In the occupancy study, both mSUV r -1 and SUV r -1 predicted comparable ED 50 of KW-6002 with the value obtained from BP ND with pharmacokinetic modeling, indicating that mSUV r À 1 and SUV r -1 are robust parameters to predict BP ND and study A 2A R occupancy in striatum. Therefore, the PET acquisition procedure can be further reduced to a 35-min static scan, starting at 25-min post tracer injection. However, we should use (m)SUV r -1 with caution especially in pathological conditions. Since the regional perfusion might have changed under such conditions and thus might have different effects on SUV r and BP ND . The usefulness of (m)SUV r -1 for striatal A 2A R quantification in other experimental setups needs to be further explored.
During the last two decades, many PET tracers have been developed for the imaging of A 2A Rs in the brain. The most promising [ 18 F]MNI-444 was recently tested in the rhesus monkeys 42 and human subjects. 18 The tracer showed good brain penetration, high BP ND values in A 2A R-rich regions and high test-retest reproducibility. However, slow kinetics might be the problem with this tracer. The tracer uptake peaked in A 2A R-rich regions at around 40-to 60-min post injection in the human and monkey brain. For the monkey study, a 120-min acquisition is required to quantify the tracer kinetics, with a 6-9% overestimation of striatal BP ND with 120-min acquisition compared with 180-min acquisition. For the human study, the 90-min acquisition overestimated striatal BP ND by $9% as compared with 210-min acquisition. In our rat study, [ 11 C]preladenant showed faster kinetics, with the highest uptake in striatum at 22.5-min post injection. A 60-min acquisition is sufficient to estimate BP ND , with marginally overestimation of BP ND of <3% on average as compared with BP ND values measured with 90-min acquisition. However, the direct comparisons between studies are difficult because of the different species and experimental setups in the studies.
Conclusions
This study shows that [ 11 C]preladenant selectively binds to A 2A Rs in the brain. The tracer has a favorable pharmacokinetic profile. The tracer displayed high BP ND in striatum with excellent test-retest reproducibility and ability to assess the changes of available A 2A Rs in the brain. A 60-min acquisition protocol using the SRTM with midbrain or occipital cortex as the reference region for kinetic modeling is the preferred method to quantify A 2A Rs in the brain. The acquisition protocol can be further reduced to a 35-min static scan to estimate BP ND with high accuracy since BP ND and SUV r are closely correlated. The results indicate that [ 11 C]preladenant is a very promising A 2A R tracer that warrants further validation in non-human primates and human subjects.
